New Scientific Evidence on BMAC Therapy in Autism — Aviv Team and Parks Hospital Novi Sad Present Important Results
- avivteamdoo
- Nov 21
- 3 min read
In the search for more effective and safer therapeutic approaches for children with Autism Spectrum Disorder (ASD), the scientific community increasingly focuses on the immune processes underlying this condition. One of the most recent and detailed studies on this topic is “Cytokine Dynamics in Autism: Analysis of BMAC Therapy Outcomes”, conducted by a medical team from Serbia.
This work represents a significant contribution to understanding the effects of BMAC therapy (bone marrow aspirate concentrate) — an innovative procedure used by both the Aviv team and Parks Hospital in Novi Sad.
What Does This Study Investigate?
The study examines how the levels of 16 different cytokines (molecules involved in immune processes) in the cerebrospinal fluid (CSF) of children with autism change before and after BMAC therapy.
Participants: 80 children (63 male, 17 female) with ASD.
Therapy: Three intrathecal BMAC injections spaced 30 days apart.
Follow-up: Six months later, the patients were divided into three groups based on clinical improvement.
Key Findings:
Children with the greatest clinical improvement showed a decrease in pro-inflammatory cytokines, suggesting the therapy helps calm inflammatory processes in the central nervous system.
The cytokine IL-27 stood out: patients with higher baseline IL-27 levels tended to respond better, making IL-27 a potential predictor of therapy success.
The therapy was well tolerated — no serious adverse effects were reported.
Why Is This Important?
This study suggests that the success of BMAC therapy might be predicted through immune biomarkers, opening the door to personalized medicine in autism. It’s a major step forward in understanding who benefits most from such therapies and why.
How the Aviv Team & Parks Hospital Apply These Findings
The Aviv team, part of Parks Hospital Novi Sad, integrates these research insights into their multidisciplinary treatment for autism.
Their approach is evidence-based, relying on the latest scientific data, including this study, to:
determine which patient groups are most likely to benefit,
emphasize immune-based treatment strategies,
individualize therapy plans.
By using real research findings, they reinforce their commitment to medicine grounded in science.
Conclusion
The paper “Cytokine Dynamics in Autism: Analysis of BMAC Therapy Outcomes” provides strong evidence that BMAC therapy can positively influence neuroimmune processes in autistic children. Importantly, it also helps identify biomarkers (like IL-27) that may predict who will benefit most, making BMAC therapy a more personalized and potentially more effective approach.
The Aviv team and Parks Hospital in Novi Sad are proud to use a therapy model aligned with cutting-edge research, offering real hope for families seeking innovative and safe treatment options.
Scientific Paper (Brief Description)
Title: Cytokine Dynamics in Autism: Analysis of BMAC Therapy Outcomes
Authors: Dusan M. Maric, Danilo Vojvodic, Dusica L. Maric, Gordana Velikic, Mihajlo Radomir, Ivana Sokolovac, Debora Stefik, Nemanja Ivkovic, Sonja Susnjevic, Miljan Puletic, Oliver Dulic, Dzihan Abazovic
What They Did:
Measured 16 cytokines in CSF of 80 ASD patients before and after BMAC therapy.
Performed three BMAC treatments (intrathecal) over 60 days.
After six months, categorized patients into three groups by clinical improvement: no/mild, moderate, major.
Found that changes in cytokine profiles (especially IL-27) correlated with improvement.
Concluded that cytokine dynamics could serve as predictive biomarkers for BMAC therapy outcome.
ResearchGate Links
Here are some useful links on ResearchGate for further reading or to direct your audience:
Direct link to the paper on ResearchGate:
Cytokine Dynamics in Autism: Analysis of BMAC Therapy Outcomes
Profile of one of the authors (Dusan M. Maric):
Comments